A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Status:
Terminated
Trial end date:
2016-11-09
Target enrollment:
Participant gender:
Summary
This is a study to determine the clinical benefit (how well the drug works), safety and
tolerability of combining a) varlilumab and ipilimumab and b) varlilumab, ipilimumab,
CDX-1401 and poly-ICLC. The study will enroll patients with unresectable Stage III or Stage
IV melanoma.